{"transactions":[{"id":707500,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.01 Par Value","published_at":"2026-07-18T01:47:48.000Z","date":"2026-07-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":10675,"price":4.09,"value":43660.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units."}],"balance_after":318668,"source":{"system":"sec-edgar","filing":"0001193125-26-308139","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899460/000119312526308139/ownership.xml","form_type":"4"}},{"id":707499,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.01 Par Value","published_at":"2026-07-18T01:47:48.000Z","date":"2026-07-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":11572,"price":4.09,"value":47329.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,991 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026."}],"balance_after":329343,"source":{"system":"sec-edgar","filing":"0001193125-26-308139","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000119312526308139/ownership.xml","form_type":"4"}},{"id":801322,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.01 Par Value","published_at":"2026-04-25T01:30:06.000Z","date":"2026-04-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":12267,"price":2.74,"value":33611.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 15, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,337 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2025."}],"balance_after":338924,"source":{"system":"sec-edgar","filing":"0001193125-26-178298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000119312526178298/ownership.xml","form_type":"4"}},{"id":828663,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-26T01:30:09.000Z","date":"2026-03-23","kind":"grant","planned":false,"acquired":true,"shares":217000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% vesting on March 23, 2027 and thereafter 1/16th quarterly."}],"balance_after":217000,"derivative":{"exercise_price":2.44,"exercise_date":"2027-03-23","expiration_date":"2036-03-23","underlying":"Common Stock, $0.01 Par Value","underlying_shares":217000},"source":{"system":"sec-edgar","filing":"0001193125-26-124726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899460/000119312526124726/ownership.xml","form_type":"4"}},{"id":828662,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Restricted Stock Unit","published_at":"2026-03-26T01:30:09.000Z","date":"2026-03-23","kind":"grant","planned":false,"acquired":true,"shares":221000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of MNKD common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above."}],"balance_after":221000,"derivative":{"underlying":"Common Stock, $0.01 Par Value","underlying_shares":221000},"source":{"system":"sec-edgar","filing":"0001193125-26-124726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000119312526124726/ownership.xml","form_type":"4"}},{"id":871062,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.01 Par Value","published_at":"2026-03-04T02:50:03.000Z","date":"2026-03-01","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":3.27,"value":16350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were purchased through the Issuer's Market Price Stock Purchase Plan. The purchase was approved by the Company's Board of Directors on March 1, 2026."}],"balance_after":348854,"source":{"system":"sec-edgar","filing":"0001193125-26-089611","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000119312526089611/ownership.xml","form_type":"4"}},{"id":1085927,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.01 Par Value","published_at":"2025-07-18T00:45:26.000Z","date":"2025-07-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":11540,"price":3.85,"value":44429.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,201 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025."}],"balance_after":343854,"source":{"system":"sec-edgar","filing":"0000950170-25-096735","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017025096735/ownership.xml","form_type":"4"}},{"id":1148136,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Restricted Stock Unit","published_at":"2025-05-16T00:34:32.000Z","date":"2025-05-13","kind":"grant","planned":true,"acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of MNKD common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above."}],"balance_after":145000,"derivative":{"underlying":"Common Stock, $0.01 Par Value","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0000950170-25-073046","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017025073046/ownership.xml","form_type":"4"}},{"id":1148135,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.01 Par Value","published_at":"2025-05-16T00:34:32.000Z","date":"2025-05-13","kind":"grant","planned":true,"acquired":true,"shares":119000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 1,593 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2024."}],"balance_after":353193,"source":{"system":"sec-edgar","filing":"0000950170-25-073046","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017025073046/ownership.xml","form_type":"4"}},{"id":1189195,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $.01 Par Value","published_at":"2025-03-29T00:20:41.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":103600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of MNKD common stock."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Correction of vesting: 4-year vesting schedule with 1/3rd of shares vesting on the second anniversary of the vesting determination date of April 22, 2024 and on each anniversary thereafter until fully vested."}],"balance_after":103600,"source":{"system":"sec-edgar","filing":"0000950170-25-047091","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017025047091/ownership.xml","form_type":"4/A","original_submission_date":"2024-05-17"}},{"id":1512530,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Restricted Stock Unit","published_at":"2024-05-18T01:00:09.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":158000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of MNKD common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The performance-based restricted stock unit will vest on July 15, 2027.  The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The performance-based restricted stock unit will vest on July 15, 2027.  The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above."}],"balance_after":158000,"derivative":{"underlying":"Common Stock, $.01 Par Value","underlying_shares":158000},"source":{"system":"sec-edgar","filing":"0000950170-24-062064","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017024062064/ownership.xml","form_type":"4"}},{"id":1512529,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $.01 Par Value","published_at":"2024-05-18T01:00:09.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":129000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of MNKD common stock."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested."}],"balance_after":232600,"source":{"system":"sec-edgar","filing":"0000950170-24-062064","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017024062064/ownership.xml","form_type":"4"}},{"id":1512528,"issuer":{"id":4792,"kind":"organization","name":"MANNKIND CORP","symbol":"MNKD"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $.01 Par Value","published_at":"2024-05-18T01:00:09.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":103600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of MNKD common stock."},{"field":"kind","element":"transactionCoding","label":"F2","text":"4-year vesting schedule with 1/4th of shares vesting on the first anniversary of the vesting determination date and on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date. The vesting determination date for this grant is April 22, 2024."}],"balance_after":103600,"source":{"system":"sec-edgar","filing":"0000950170-24-062064","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899460/000095017024062064/ownership.xml","form_type":"4"}},{"id":2494939,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-24T16:10:18.000Z","date":"2021-11-24","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"$3.40 plus two CVRs per share underlying the stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Option shares shall vest as follows: 1/48th of the option shares shall vest on December 1, 2019 and 1/48th shall vest monthly thereafter, subject to Reporting Person's Continuous Service as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":4.7,"expiration_date":"2029-11-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001328143-21-000092","document":"wf-form4_163778819925663.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000092/wf-form4_163778819925663.xml","form_type":"4"}},{"id":2494938,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-24T16:10:18.000Z","date":"2021-11-24","kind":"disposition_to_issuer","acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"$1.29 plus two CVRs per share underlying the stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with May 1, 2019, subject to Reporting Person's Continuous Service as of each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":6.81,"expiration_date":"2029-04-07","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001328143-21-000092","document":"wf-form4_163778819925663.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000092/wf-form4_163778819925663.xml","form_type":"4"}},{"id":2494937,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-24T16:10:18.000Z","date":"2021-11-24","kind":"other","acquired":false,"shares":163767,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. (\"Parent\") and Supernus Reef, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 24, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights (\"CVRs\" and, collectively with the cash amount, the \"Per Share Price\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"A portion of this amount consists of unvested restricted stock units, including PRSUs (\"RSUs\"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001328143-21-000092","document":"wf-form4_163778819925663.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000092/wf-form4_163778819925663.xml","form_type":"4"}},{"id":2494936,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-24T16:10:18.000Z","date":"2021-11-24","kind":"grant","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of performance-based restricted stock units (\"PRSUs\") granted to the reporting person on March 2, 2021. The performance conditions associated with the PRSUs had not yet occurred. Pursuant to the Merger Agreement (as defined below), immediately prior to the effective time of the Merger (as defined below), the PRSU was deemed to have vested."}],"balance_after":163767,"source":{"system":"sec-edgar","filing":"0001328143-21-000092","document":"wf-form4_163778819925663.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000132814321000092/wf-form4_163778819925663.xml","form_type":"4"}},{"id":2774371,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-23T18:02:23.000Z","date":"2021-03-22","kind":"sale","acquired":false,"shares":2422,"price":5.48,"value":13272.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $5.40 to $5.52.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":145017,"source":{"system":"sec-edgar","filing":"0001209191-21-022631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919121022631/doc4.xml","form_type":"4"}},{"id":2812076,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-03-03T16:56:57.000Z","date":"2021-03-02","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 1/3rd of the total number of Restricted Stock Units will vest on each of March 1, 2022, March 1, 2023 and March 1, 2024, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":147439,"source":{"system":"sec-edgar","filing":"0001209191-21-016939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919121016939/doc4.xml","form_type":"4"}},{"id":2888351,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-01T21:39:36.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":3821,"price":6.36,"value":24301.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $6.33 to $6.49.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":72439,"source":{"system":"sec-edgar","filing":"0001209191-21-006601","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919121006601/doc4.xml","form_type":"4"}},{"id":2898907,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-22T17:29:37.000Z","date":"2021-01-20","kind":"sale","acquired":false,"shares":2630,"price":4.41,"value":11598.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $4.35 to $4.51.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":76260,"source":{"system":"sec-edgar","filing":"0001209191-21-004931","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919121004931/doc4.xml","form_type":"4"}},{"id":2996336,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-11-02T16:44:37.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":2050,"price":3.21,"value":6580.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $3.16 to $3.24.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":78890,"source":{"system":"sec-edgar","filing":"0001209191-20-056424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919120056424/doc4.xml","form_type":"4"}},{"id":3200348,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-19T16:21:45.000Z","date":"2020-03-17","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on January 31, 2021."}],"balance_after":80940,"source":{"system":"sec-edgar","filing":"0001209191-20-020266","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919120020266/doc4.xml","form_type":"4"}},{"id":3303825,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-01-23T17:33:48.000Z","date":"2020-01-21","kind":"sale","acquired":false,"shares":1269,"price":5.92,"value":7512.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $5.90 to $5.93.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":70940,"source":{"system":"sec-edgar","filing":"0001209191-20-004717","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919120004717/doc4.xml","form_type":"4"}},{"id":3376180,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-08T16:48:06.000Z","date":"2019-11-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shares shall vest as follows: 1/48th of the option shares shall vest on December 1, 2019 and 1/48th shall vest monthly thereafter, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":50000,"derivative":{"exercise_price":4.7,"expiration_date":"2029-11-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-19-055838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919119055838/doc4.xml","form_type":"4"}},{"id":3376179,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-11-08T16:48:06.000Z","date":"2019-11-07","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 1/4th on each of 11/1/20, 11/1/21, 11/1/22 and 11/1/23, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":72209,"source":{"system":"sec-edgar","filing":"0001209191-19-055838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919119055838/doc4.xml","form_type":"4"}},{"id":3457320,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2019-07-23T18:06:11.000Z","date":"2019-07-22","kind":"sale","acquired":false,"shares":1082,"price":6,"value":6492.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units."}],"balance_after":47209,"source":{"system":"sec-edgar","filing":"0001209191-19-042978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919119042978/doc4.xml","form_type":"4"}},{"id":3558293,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-10T16:31:03.000Z","date":"2019-04-08","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with May 1, 2019, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":37500,"derivative":{"exercise_price":6.81,"expiration_date":"2029-04-07","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001209191-19-024242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919119024242/doc4.xml","form_type":"4"}},{"id":3558292,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2019-04-10T16:31:03.000Z","date":"2019-04-08","kind":"grant","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2020, March 20, 2021, March 20, 2022 and March 20, 2023, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":48291,"source":{"system":"sec-edgar","filing":"0001209191-19-024242","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919119024242/doc4.xml","form_type":"4"}},{"id":3582738,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2019-03-21T16:43:05.000Z","date":"2019-03-20","kind":"sale","acquired":false,"shares":1185,"price":8,"value":9480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $7.94 to $8.03.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":29541,"source":{"system":"sec-edgar","filing":"0001209191-19-020779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919119020779/doc4.xml","form_type":"4"}},{"id":3716786,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2018-12-28T16:25:46.000Z","date":"2018-12-27","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on July 20, 2019 and January 20, 2020 and 50% of the total number of Restricted Stock Units will vest on January 20, 2021, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":30726,"source":{"system":"sec-edgar","filing":"0001209191-18-064320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919118064320/doc4.xml","form_type":"4"}},{"id":3718813,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2018-12-26T17:09:02.000Z","date":"2018-12-20","kind":"sale","acquired":false,"shares":228,"price":7.51,"value":1712.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $7.50 to $7.51.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 696 shares purchased on 5/31/18 through the issuer's employee stock purchase plan."}],"balance_after":18226,"source":{"system":"sec-edgar","filing":"0001209191-18-064120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919118064120/doc4.xml","form_type":"4"}},{"id":3984821,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2018-03-22T17:54:36.000Z","date":"2018-03-21","kind":"sale","acquired":false,"shares":567,"price":25.98,"value":14730.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $25.83 to $26.00.  The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":17758,"source":{"system":"sec-edgar","filing":"0001209191-18-021314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919118021314/doc4.xml","form_type":"4"}},{"id":4002863,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-09T20:51:43.000Z","date":"2018-03-06","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with April 1, 2018, subject to Reporting Person's Continuous Service as of each such date."}],"balance_after":30000,"derivative":{"exercise_price":25.66,"expiration_date":"2028-03-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-18-018674","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919118018674/doc4.xml","form_type":"4"}},{"id":4002862,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2018-03-09T20:51:43.000Z","date":"2018-03-06","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2019, March 20, 2020, March 20, 2021 and March 20, 2022, subject to Reporting Person's Continuous Service as of each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 920 shares purchased on 11/30/17 through the issuer's employee stock purchase plan."}],"balance_after":18325,"source":{"system":"sec-edgar","filing":"0001209191-18-018674","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919118018674/doc4.xml","form_type":"4"}},{"id":4188787,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-10T19:00:18.000Z","date":"2017-10-06","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest and become exercisable in equal monthly installments on the 1st of every month over four years with the first vesting on October 1, 2017."}],"balance_after":15000,"derivative":{"exercise_price":23.11,"expiration_date":"2027-10-05","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-056550","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919117056550/doc4.xml","form_type":"4"}},{"id":4188786,"issuer":{"id":133085,"kind":"organization","name":"Adamas Pharmaceuticals Inc","symbol":"ADMS"},"owners":[{"id":29919,"kind":"person","name":"Prentiss Christopher B","position":1,"cik":"0001717583","reported_name":"Prentiss Christopher B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2017-10-10T19:00:18.000Z","date":"2017-10-06","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest 1/4th on each of December 20, 2018, December 20, 2019, December 20, 2020 and December 20, 2021."}],"balance_after":12405,"source":{"system":"sec-edgar","filing":"0001209191-17-056550","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328143/000120919117056550/doc4.xml","form_type":"4"}}]}